Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE

• Published in: Biochemical pharmacology 2020-10, Vol.180, p.114126-114126, Article 114126
• Main Authors: Qiao, Jianghua, Chen, Yibing, Mi, Yanjun, Jin, Huan, Wang, Lina, Huang, Ting, Li, Haolong, Song, Yucen, Cao, Jun, Wu, Baoyan, Wang, Qiming, Zou, Zhengzhi
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Apoptosis - genetics; BET inhibition; Cell Line, Tumor; Cell Survival - drug effects; Cell Survival - genetics; Coculture Techniques; Drug Resistance, Neoplasm - drug effects; Drug Resistance, Neoplasm - genetics; Female; Humans; I-kappa B Kinase - genetics; IKBKE; Macrophages; MCF-7 Cells; Mice, Nude; Proteins - antagonists & inhibitors; STAT3; THP-1 Cells; Triple Negative Breast Neoplasms - metabolism; Triple Negative Breast Neoplasms - pathology; Triple-negative breast cancer; Tumor-Associated Macrophages - metabolism; Tumor-Associated Macrophages - pathology; Up-Regulation; Xenograft Model Antitumor Assays
• ISSN: 0006-2952; 1873-2968
• DOI: 10.1016/j.bcp.2020.114126

[Display omitted] BET inhibitors (BETi) exhibit a strong anti-tumor activity in triple-negative breast cancer (TNBC). However, BETi resistance has been reported in TNBC. The mechanisms of resistance have not been demonstrated. Tumor-associated macrophages (TAMs) are frequently involved in cancer cells resistance to chemotherapy, also associated with poor prognosis in TNBC. However, the role of TAMs in BETi resistance remains unknown. Here, we found that BETi JQ1 and I-BET151 exerted anti-tumor effects in TNBC by decreasing IKBKE expression to attenuate NF-κB signaling. TAMs have been reported to associate with chemoresistance in breast cancer. Here, we firstly found that TNBC-stimulated TAMs activated NF-κB signaling by upregulating IKBKE expression to enhance breast cancer cells resistance to BETi. The IKBKE levels were also proved to be higher in clinical TNBC tissues than Non-TNBC tissues, suggesting feedback induction of IKBKE expression by TNBC-stimulated TAMs in TNBC. Moreover, the induction of IKBKE by TAMs in TNBC cells was identified to be associated with STAT3 signaling, which was activated by TAM-secreted IL-6 and IL-10. Lastly, the combination of inhibitors of BET and STAT3 exerted a synergistic inhibition effects in TAM-cocultured or TAM CM-treated TNBC cells in vitro and in vivo. Altogether, our findings illustrated TNBC-activated macrophages conferred TNBC cells resistance to BETi via IL-6 or IL-10/STAT3/IKBKE/NF-κB axis. Blockade of IKBKE or double inhibition of BET and STAT3 might be a novel strategy for treatment of TNBC.